These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

893 related articles for article (PubMed ID: 25458200)

  • 1. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
    Serisier DJ; Martin ML; McGuckin MA; Lourie R; Chen AC; Brain B; Biga S; Schlebusch S; Dash P; Bowler SD
    JAMA; 2013 Mar; 309(12):1260-7. PubMed ID: 23532242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis.
    Choo JM; Abell GCJ; Thomson R; Morgan L; Waterer G; Gordon DL; Taylor SL; Leong LEX; Wesselingh SL; Burr LD; Rogers GB
    mSphere; 2018 Apr; 3(2):. PubMed ID: 29669883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial.
    Burr LD; Rogers GB; Chen AC; Hamilton BR; Pool GF; Taylor SL; Venter D; Bowler SD; Biga S; McGuckin MA
    Ann Am Thorac Soc; 2016 Oct; 13(10):1697-1703. PubMed ID: 27464029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
    Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
    Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel microbiota stratification system predicts future exacerbations in bronchiectasis.
    Rogers GB; Zain NM; Bruce KD; Burr LD; Chen AC; Rivett DW; McGuckin MA; Serisier DJ
    Ann Am Thorac Soc; 2014 May; 11(4):496-503. PubMed ID: 24592925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis.
    Taylor SL; Rogers GB; Chen AC; Burr LD; McGuckin MA; Serisier DJ
    Ann Am Thorac Soc; 2015 May; 12(5):701-7. PubMed ID: 25679336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
    Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
    Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition.
    Rogers GB; van der Gast CJ; Cuthbertson L; Thomson SK; Bruce KD; Martin ML; Serisier DJ
    Thorax; 2013 Aug; 68(8):731-7. PubMed ID: 23564400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.
    Chalmers JD; Boersma W; Lonergan M; Jayaram L; Crichton ML; Karalus N; Taylor SL; Martin ML; Burr LD; Wong C; Altenburg J
    Lancet Respir Med; 2019 Oct; 7(10):845-854. PubMed ID: 31405828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
    Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
    JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
    Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG
    Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
    VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
    Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
    Serisier DJ; Bilton D; De Soyza A; Thompson PJ; Kolbe J; Greville HW; Cipolla D; Bruinenberg P; Gonda I;
    Thorax; 2013 Sep; 68(9):812-7. PubMed ID: 23681906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
    Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
    Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
    Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Taylor SL; Woodman RJ; Chen AC; Burr LD; Gordon DL; McGuckin MA; Wesselingh S; Rogers GB
    Thorax; 2017 Apr; 72(4):304-310. PubMed ID: 27503233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.
    Haworth CS; Shteinberg M; Winthrop K; Barker A; Blasi F; Dimakou K; Morgan LC; O'Donnell AE; Ringshausen FC; Sibila O; Thomson RM; Carroll KJ; Pontenani F; Castellani P; Chalmers JD;
    Lancet Respir Med; 2024 Oct; 12(10):787-798. PubMed ID: 39270696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.